What 'bioidentical' means in molecular terms
Bioidentical hormones are substances with a chemical structure identical to the hormones produced by human ovaries, testes, and adrenal glands. This is not marketing language—it describes molecular identity confirmed by mass spectrometry. 17β-estradiol, the primary estrogen made by ovaries, has the formula C₁₈H₂₄O₂. The FDA-approved transdermal estradiol in a Vivelle-Dot patch has that same formula. Micronized progesterone—Prometrium capsules, for instance—is chemically identical to corpus luteum progesterone. By contrast, conjugated equine estrogens (Premarin) contain estrone sulfate and equilin derived from pregnant mares' urine, and medroxyprogesterone acetate (Provera) is a synthetic progestin that does not exist in nature.
The confusion arises because 'bioidentical hormone replacement therapy' (BHRT) has become a marketing term used by compounding pharmacies to differentiate their products from conventional HRT. Many patients hear 'bioidentical' and assume it means safer, more natural, or custom-tailored. In our clinic, we use FDA-approved bioidentical formulations—transdermal estradiol, oral micronized progesterone, and occasionally transdermal testosterone—because they have standardized dosing, regulatory oversight, and decades of pharmacokinetic data. We rarely prescribe compounded preparations except in cases of documented allergy to an excipient, and we never use hormone pellets.
FDA-approved bioidentical formulations and their evidence base
The strongest safety data for menopausal hormone therapy come from regimens using transdermal 17β-estradiol and oral micronized progesterone. A 2017 re-analysis of the Women's Health Initiative data showed that the elevated cardiovascular and breast cancer risks seen with oral conjugated estrogens plus medroxyprogesterone acetate (CEE+MPA) do not apply uniformly to other regimens. Transdermal estradiol avoids hepatic first-pass metabolism, leading to more favorable lipid and coagulation profiles compared to oral estrogen. The E3N French cohort study followed 80,000 postmenopausal women and found that users of transdermal estradiol with micronized progesterone had no increased risk of venous thromboembolism compared to non-users, whereas oral estrogen—even bioidentical oral estradiol—was associated with a 1.4-fold increase.
Oral micronized progesterone has a gentler metabolic profile than synthetic progestins. A 2018 JAMA study of over 80,000 women reported that micronized progesterone carried a significantly lower breast cancer risk than medroxyprogesterone or norethisterone when combined with estrogen. The absolute increase in risk remained modest—around 1 additional case per 1,000 women over five years—but the distinction matters when counseling patients with a family history of breast cancer. We initiate most perimenopausal and early postmenopausal patients on a 0.05 mg twice-weekly estradiol patch with 100–200 mg nightly oral micronized progesterone, titrating based on symptom control and endometrial protection. This is not custom compounding; these are FDA-regulated products with predictable pharmacokinetics.
The case against unregulated compounded hormone preparations
Compounded bioidentical hormones are preparations made by a pharmacy that mixes active ingredients—often estradiol, estriol, progesterone, testosterone, or DHEA—into creams, troches, or pellets. The FDA does not approve compounded drugs; it regulates the practice of compounding under specific conditions. This means no pre-market efficacy or safety review, no lot-to-lot consistency testing, and no package insert with dosing guidance. A 2001 Government Accountability Office report sampled compounded hormone preparations and found potency variations of 200% or more within the same batch. We have seen patients arrive on compounded troche regimens with supraphysiologic estradiol levels above 400 pg/mL and no progestogen—leaving the endometrium unprotected.
The most concerning modality is the testosterone pellet, often marketed to women for 'energy' or libido. These are typically 75–100 mg pellets implanted subcutaneously every 3–4 months. Once in, they cannot be removed if a patient develops hirsutism, acne, or supraphysiologic testosterone levels. We have managed several patients transferred to us after pellet insertion resulted in total testosterone levels exceeding 300 ng/dL—well above the physiologic range for premenopausal women (15–70 ng/dL). There is no FDA-approved testosterone formulation for women in the United States; the 2019 Global Consensus Position Statement on testosterone therapy in women recommends a target range of 30–50 ng/dL and prefers short-acting transdermal formulations. We occasionally prescribe compounded testosterone cream or off-label low-dose AndroGel, always with baseline and 4-week follow-up labs.
Breast cancer risk: nuance beyond the headlines
The relationship between menopausal hormone therapy and breast cancer is not binary. The WHI trial showed an increase in invasive breast cancer with CEE+MPA after 5.6 years, but the estrogen-alone arm (CEE without progestin) in hysterectomized women showed a reduction in breast cancer incidence over 7 years—suggesting that the synthetic progestin drove much of the risk. The 2018 JAMA study mentioned earlier stratified by progestogen type: compared to estrogen alone, adding micronized progesterone increased breast cancer incidence by 0.8 cases per 1,000 women per year, whereas adding medroxyprogesterone increased it by 2.7 cases per 1,000 women per year. Duration matters—most guidelines agree that risk becomes appreciable after 5 years of continuous combined therapy.
We discuss this data transparently during consultations. For a 52-year-old patient with moderate vasomotor symptoms and no personal or strong family history of breast cancer, the absolute increase in risk from a bioidentical transdermal estradiol plus micronized progesterone regimen is small and often outweighed by quality-of-life gains and potential bone and cardiovascular benefits when initiated near menopause. For a patient with a BRCA1 mutation or prior ductal carcinoma in situ, we typically defer systemic hormone therapy and explore non-hormonal options like low-dose paroxetine or cognitive behavioral therapy for insomnia. Risk stratification is individualized—there is no blanket recommendation.
The regulatory landscape and what patients should ask
The FDA issued a statement in 2008 clarifying that compounded bioidentical hormones are not safer or more effective than FDA-approved products, despite marketing claims. The agency reiterated this in a 2020 updated guidance. In clinical practice, this means a patient on a compounded 'biest' cream (80% estriol, 20% estradiol) is receiving an unstudied formulation with unknown breast and endometrial effects. Estriol is a weak estrogen used in Europe for urogenital atrophy, but high-dose systemic estriol has not been evaluated in long-term safety trials. When a patient brings us a compounded prescription, we first obtain hormone levels, then transition them to an FDA-approved equivalent with defined dosing and known kinetics.
Patients should ask their provider: Is this formulation FDA-approved? If compounded, what is the clinical rationale—documented allergy, unavailable commercial dose? Will I have follow-up hormone levels to confirm appropriate dosing? Am I receiving endometrial protection if I have a uterus? These questions matter. We have no financial interest in steering patients toward one product over another; we prescribe what the literature supports and what we can monitor reliably. In the San Gabriel Valley, we see a high volume of patients who have been placed on compounded regimens by wellness clinics. The transition to evidence-based bioidentical therapy often improves symptoms while lowering risk.
How we prescribe bioidentical hormones in practice
Our standard menopausal hormone therapy initiation involves a 30-minute consultation reviewing symptom burden, personal and family history, and baseline labs including estradiol, FSH, TSH, and lipids. For a woman within 10 years of menopause with an intact uterus, we typically start a 0.05 mg estradiol patch applied twice weekly and 100 mg micronized progesterone taken at bedtime. At 6 weeks, we assess symptom response and check a trough estradiol level (target 40–100 pg/mL for symptom control). If vasomotor symptoms persist, we increase the patch to 0.075 mg or switch to a different delivery system—gel, spray, or oral micronized estradiol if the patient prefers.
For women who have undergone hysterectomy, estrogen-only therapy is appropriate; we use the same transdermal estradiol but omit progesterone. If libido is a prominent concern and estradiol alone does not address it, we consider adding transdermal testosterone at a low dose—typically 1–2 mg daily of compounded cream or a pea-sized amount of 1% AndroGel applied to the upper arm. We recheck testosterone at 4 weeks, targeting a total level of 30–50 ng/dL. We do not use pellets. We do not prescribe DHEA systemically unless there is documented adrenal insufficiency. We do not combine five different hormones into a single 'custom' cream. The goal is the lowest effective dose of the fewest agents, monitored with objective data.
